In an otherwise healthy adult with acute cervical muscle pain and no history of gastrointestinal ulcer disease, severe renal impairment, uncontrolled hypertension, or high cardiovascular risk, is etoricoxib an appropriate treatment?

Etoricoxib for Acute Cervical Muscle Pain in Low-Risk Patients

Yes, etoricoxib is an appropriate treatment option for an otherwise healthy adult with acute cervical muscle pain who lacks gastrointestinal, renal, cardiovascular, or hypertensive contraindications, though it should not be a first-line choice given available safer alternatives. 1

Treatment Hierarchy for Acute Cervical Pain

For acute cervical pain without "red flags" (such as fever, weight loss, neurological deficits, or inflammatory markers), imaging is typically unnecessary and clinical management should proceed directly. 1

Recommended Stepped-Care Approach

The American Heart Association recommends a hierarchical approach for musculoskeletal pain management, particularly relevant when considering NSAIDs: 1

First-line agents (lowest cardiovascular risk):

• Acetaminophen
• Non-acetylated salicylates
• Tramadol or short-term narcotic analgesics 1

Second-line agents:

• Non-selective NSAIDs with minimal COX-2 selectivity
• Naproxen (if NSAID required) 1

Third-line agents:

• NSAIDs with COX-2 activity, including etoricoxib 1

Etoricoxib-Specific Considerations

Efficacy Profile

Etoricoxib demonstrates effective analgesia for musculoskeletal pain, with clinical trials showing at least similar efficacy to traditional NSAIDs for acute pain conditions. 2 The drug provides rapid, steady-state analgesic effects with convenient once-daily dosing due to its approximately 20-hour elimination half-life. 3

Safety Profile in Low-Risk Patients

Cardiovascular considerations:

• Etoricoxib carries similar cardiovascular thrombotic risk as diclofenac, both lying on the more COX-2-selective end of the spectrum. 1
• Meta-analysis data comparing etoricoxib to placebo did not demonstrate statistically significant differences in serious vascular events, unlike celecoxib which showed increased risk. 4
• However, the drug should still be used at the lowest effective dose for the shortest duration. 5

Gastrointestinal safety:

• Etoricoxib demonstrates superior gastrointestinal tolerability compared to traditional NSAIDs, with 50% reduction in discontinuation rates due to GI adverse events versus diclofenac. 6
• This represents a potential advantage in your patient without ulcer history. 2

Blood pressure effects:

• Etoricoxib shows less pronounced effects on diurnal blood pressure rhythm compared to nimesulide, diclofenac, and meloxicam. 7
• However, it is contraindicated in uncontrolled hypertension and requires blood pressure monitoring during treatment. 5, 6

Renal considerations:

• No dose adjustment is necessary in mild-to-moderate renal impairment, though severe impairment (CrCl <20 mL/min) is not recommended. 5
• Renal adverse effects appear similar to other NSAIDs. 3

Practical Prescribing Guidance

If etoricoxib is selected for your patient:

• Use the lowest effective dose (typically 60-90 mg once daily for acute pain) 2
• Limit duration to the shortest period necessary for symptom control 5
• Monitor blood pressure during treatment initiation and throughout therapy 5
• Ensure adequate hydration before initiating therapy 5
• Remain alert for signs of cardiovascular events, GI complications, or hepatotoxicity 5

Critical Caveats

Common pitfalls to avoid:

• Do not assume etoricoxib is "safer" than traditional NSAIDs simply because it's a COX-2 inhibitor—cardiovascular risk remains comparable to diclofenac. 1
• Do not use in patients with unrecognized cardiovascular risk factors without thorough assessment. 6
• Avoid in patients with aspirin triad (asthma, rhinitis, nasal polyps). 5
• Do not use after 30 weeks gestation due to risk of premature ductus arteriosus closure. 5

When etoricoxib is particularly appropriate:

• Patients at high risk for GI complications but low cardiovascular risk 6, 8
• When once-daily dosing improves compliance 2
• When hepatotoxicity concerns exist (compared to some traditional NSAIDs) 8

Given your patient's low-risk profile, etoricoxib represents a reasonable option, though starting with acetaminophen or a less COX-2-selective NSAID like naproxen would align better with guideline-recommended stepped care. 1, 9